{"prompt": "['Alliance A221502', 'Differences in length of stay between arms will be tested using a two-sample, two-sided t-', 'test. Wilcoxon nonparametric testing will be used for analyzing continuous outcomes that', \"are skewed and not approximately normally distributed. Fisher's exact tests will be used to\", 'test for differences in categorical variables between arms. All tests will be two-sided with a', '0.05 significance level. Linear models will be created to test the effects of treatment after', 'adjusting for the baseline characteristics of age, gender, and lung function.', '11.4 Supplementary Analysis Plans', '11.4.1 Secondary Enppoints', 'End points that will address AIM 2 (baseline and at 3 and 6 months after hospital discharge):', 'Post-Operative Pulmonary Complications: The following events will be considered post-', 'operative pulmonary complications: pneumonia (new infiltrate + either fever (>38.5 C) and', 'white cell count >11,000 or fever and purulent secretions), severe atelectasis (requiring', 'bronchoscopy), prolonged chest tubes (>6 days), and respiratory failure (intubation or', 'prolonged mechanical ventilation (>24 hours). These outcomes will be obtained by chart', 'review by a nurse trained in the abstraction of the desired outcomes from the medical records', 'and blinded to treatment assignment.', 'Chronic Respiratory Questionnaire (CRQ) (four domains: dyspnea, fatigue, emotional', 'function and mastery). This instrument will be the primary tool to assess QoL given that it', 'was specifically designed for COPD. Specifically, the CRQ represents one of the most well-', 'known, widely-applied, and psychometrically-sound patient reported outcomes for use in', 'clinical trials involving patients with COPD. The CRQ has been validated and has', 'demonstrated a reliable quality of life measures for patients with chronic airflow limitations.', 'A 0.5 point will be considered significant and was considered in the sample size calculation', 'as that difference as is the well-established MCID (minimally clinically important', 'difference) for the instrument. Analysis for the QOL outcomes will be identical to that for', 'the primary endpoint. We include the scores from the dyspnea questionnaire under the', 'generic umbrella term as a domain of QOL.', 'LASA (single-item numerical analogue quality of life Questionnaire) individual QOL', 'domain scores. All of these questionnaires have been validated previously for lung cancer', 'patient populations and for assessment of patient-reported outcomes in similar trials. LASA', 'items have been validated as general measures of global QOL dimensional constructs in', 'numerous settings and have been constructed and validated at Mayo Clinic for use in cancer', 'patients. These single-item assessments have become the most used assessments in all NCI-', 'sponsored cancer control studies.28', '11.4.2 Secondary Analysis', 'Longitudinal analysis for the relationship between QOL and the intervention will be handled', 'by repeated measures analysis of variance modeling and multiple regressions. Finally, a', 'logistic regression model will be used to identify which variables are most closely associated', 'with the dependent variable of patients who experience either clinically significant deficits', 'in QOL (one regression model). The modeling processes will include the aforementioned', 'covariates to control for spurious correlations.', '21', 'NCI Version Date 7/28/2017', 'Update #3']['Alliance A221502', '11.5 Study Monitoring', '11.5.1 Adverse Event Stopping Rule', 'Not applicable.', '11.5.2 Accrual Monitoring Stopping Rule', 'Slow Accrual: Patient accrual will be closely monitored by the investigators and secondary', 'statistician on a monthly basis. If the accrual rate falls below 50% of expected accrual rate,', 'investigators will carefully review feedback from sites and consider taking measures to', 'encourage patient enrollment.', '11.5.3 This study will be monitored by the Alliance Data Safety Monitoring Board (DSMB), an', 'NCI-approved functioning body. Reports containing efficacy, adverse event, and', 'administrative information will be provided to the DSMB every month as per NCI', 'guidelines.', '11.6 Study Reporting', 'At study activation, this study will have been registered within the \"ClinicialTrials.gov\" web', 'site. The Primary and Secondary Endpoints (i.e., \"Outcome Measures\") along with other', 'required information for this study will be reported on ClinicalTrials.gov.', '11.7', 'Descriptive Factors', 'None.', '11.8', 'Inclusion of Women and Minorities', 'Inclusion of Women: Based upon the gender distribution of patients from past studies and the', 'gender distribution with ICD-9 codes for COPD/ lung cancer, we anticipate a female to male', 'ratio of 5/6 ratio.', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Racial Categories', 'Not Hispanic or', 'Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/ Alaska Native', '1', '1', '0', '0', '2', 'Asian', '5', '3', '1', '1', '10', 'Native Hawaiian or Other Pacific', '1', '1', '0', '0', '2', 'Islander', 'Black or African American', '14', '9', '1', '1', '25', 'White', '80', '57', '4', '4', '145', 'More Than One Race', '4', '3', '2', '1', '10', 'Total', '105', '74', '8', '7', '194', '22', 'NCI Version Date 7/28/2017', 'Update #3']\n\n###\n\n", "completion": "END"}